ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint
– The ENB-003 in combination with KEYTRUDA® (pembrolizumab) was well tolerated
– Promising preliminary efficacy signals with 33% disease control rate (DCR) across all cohorts
– Efficacy appears to correlate with endothelin B receptor (ETBR) expression: 83% DCR in ETBR-Hi patients in cohort 6 (RP2D)
– Platinum refractory/ resistant microsatellite stable ovarian cancer patients with 80% DCR across all cohorts
Comments are closed.